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ABSTRACT: The binding sites of Cys-loop receptors are formed from at least six loops (A-F). Here we
have used mutagenesis, radioligand binding, voltage clamp electrophysiology, and homology modeling
to probe the role of two residues in loop A of the 5-HT3 receptor: Asn128 and Glu129. The data show
that substitution of Asn128, with a range of alternative natural and unnatural amino acids, changed the
EC50 (from ∼10-fold more potent to ∼10-fold less potent than that of the wild type), increased the maximal
peak current for mCPBG compared to 5-HT (Rmax)2 -19-fold, and decreased nH, indicating this residue
is involved in receptor gating; we propose Asn128 faces away from the binding pocket and plays a role
in facilitating transitions between conformational states. Substitutions of Glu129 resulted in functional
receptors only when the residue could accept a hydrogen bond, but with both these and other substitutions,
no [3H]granisetron binding could be detected, indicating a role in ligand binding. We propose that Glu129
faces into the binding pocket, where, through its ability to hydrogen bond, it plays a critical role in ligand
binding. Thus, the data support a modiﬁed model of the 5-HT3 receptor binding site and show that loop
A plays a critical role in both the ligand binding and function of this receptor.
5-HT3 receptors are members of the Cys-loop family of
ligand-gated ion channels, a group that also includes nicotinic
acetylcholine (nACh),
1 GABAA, and glycine receptors. The
receptors function as a pentameric arrangement of subunits,
with each subunit having a large extracellular N-terminal
region and four transmembrane helices (M1-M4). The
extracellular domain contains the ligand binding site, and
the availability of the high-resolution structure of the
acetylcholine binding protein (AChBP), which is homologous
to this region, has enabled the construction of a series of
homology models of the extracellular domains of several
Cys-loop receptors, including nACh, GABAA, and 5-HT3
receptors (1–7). These models support experimental data that
indicate that ligand binding is coordinated by six noncon-
tiguous regions, loops A-F, of the linear sequence (Figure
1A). The recent structure determination of the extracellular
domain of a nACh receptor R subunit provides further
support for these models (8).
Studies of nACh, GABAA, and 5-HT3 receptors indicate
that loop A makes an important contribution to receptor
function (9–13). Loop A residues Asn128, Glu129, and
Phe130 are conserved in all known 5-HT3A and 5-HT3B
receptor subunits (Figure 1B), and it is therefore likely
that these residues are important for receptor binding and/
or gating. The structure of AChBP indicates that only a
single loop A residue contributes to the binding pocket,
but identifying the precise 5-HT3 receptor residue in the
equivalent location is not straightforward, as loop A
exempliﬁes a region in which the alignment of subunit
residues with AChBP is difﬁcult. A model of the 5-HT3
receptor binding pocket predicts that the side chain of
Asn128 faces into the binding pocket and interacts with
5-HT via a hydrogen bond (5), but a later study indicates
that Asn128 does not participate in ligand binding (13).
This study suggested a new orientation with Glu129
replacing Asn128 in the binding pocket but did not provide
any experimental evidence of Glu129 mutant receptors
to support this hypothesis. Phe130 has also been previ-
ously proposed as a ligand binding residue, as its
substitution with Asn created receptors that respond to
ACh (12), albeit at high concentrations. However, a more
recent study (13) indicates that it is unlikely to be in the
binding pocket, as substitutions have only small or no
effects on antagonist binding, and the effect of ACh can
be explained as mutations at this site can create receptors
that are more sensitive to nonspeciﬁc agonists such as
ACh, which will activate 5-HT3 receptors at high con-
centrations (>1 mM). In this study, we have therefore
concentrated on Asn128 and Glu129, substituting them
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2) to probe potential interactions with 5-HT. The data
suggest that Glu129 is directly involved in ligand binding
by participating in a critical hydrogen bond with the
FIGURE 1: (A) Model of two adjacent subunits of the 5-HT3 receptor (based on ref 5) showing the positions of the binding loops (black)
and residues Asn128 and Glu129 (space ﬁlled). (B) Alignment of the binding loop A region from various 5-HT3A and 5-HT3B receptor
subunits, the Torpedo nACh receptor R1 subunit, and AChBP. Binding loop A was originally deﬁned as being equivalent to W121-N128
(29), but recent data suggest it may be longer (this study and ref 11). Residues with similar chemical properties are highlighted in gray. The
Asn, Glu, and Phe residues conserved in all 5-HT3 receptor subunits are boxed. The numbering is that of the mouse 5-HT3A receptor
subunit.
FIGURE 2: Structures of the side chains of the natural and unnatural amino acids used in these studies. Akp is aminoketopentanoic acid and
Nha nitrohomoalanine.
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evidence that the revised model may be correct.
EXPERIMENTAL PROCEDURES
Mutagenesis and Preparation of cRNA and Oocytes.
Mutant 5-HT3 receptor subunits were cloned into pcDNA3.1
(Invitrogen) containing the complete coding sequence for the
mouse 5-HT3A receptor subunit (GenBank accession number
Q6J1J7). Mutagenesis reactions were performed using the
Kunkel method and conﬁrmed by DNA sequencing. Har-
vested stage V-VI Xenopus oocytes were injected with 5
ng of cRNA produced by in vitro transcription using the
mMESSAGE mMACHINE kit (Ambion) from cDNA sub-
cloned into pGEMHE as previously described (14). The
unnatural amino acids nitrohomoalanine (Nha) and 2-amino-
4-ketopentanoic acid (Akp) were incorporated using nonsense
suppression as previously described (14). Electrophysiologi-
cal measurements were performed 24-72 h postinjection.
Synthesis of tRNA and dCA Amino Acids. This was
conducted as described previously (14). Brieﬂy, unnatural
amino acids (Figure 2) were chemically synthesized as
nitroveratryloxycarbonyl (NVOC)-protected cyanomethyl
esters and coupled to the dinucleotide dCA, which was then
enzymatically ligated to 74-mer THG73 tRNACUA as detailed
previously (15). Immediately prior to co-injection with
cRNA, aminoacyl-tRNA was deprotected by photolysis (16).
Typically, 5 ng of total cRNA was injected with 25 ng of
tRNA-aa in a total volume of 50 nL. For a control, cRNA
was injected with THG 74-mer tRNA (no unnatural amino
acid attached).
Characterization of Mutant Receptors. Agonist-induced
currents were recorded at 22-25 °C from individual oocytes
using either conventional two-electrode voltage clamp elec-
trophysiology or the higher-throughput automated Opus-
Xpress system (MDS Axon Instruments); these two systems
gave the same results. 5-HT, m-chlorophenylbiguanide
(mCPBG), 5-ﬂuorotryptamine (5-FT), and tryptamine were
stored as 20-100 mM aliquots at -20 °C, diluted in Ca-
free ND96 buffer [96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
and 5 mM HEPES (pH 7.5)]. Glass microelectrodes were
backﬁlled with 3 M KCl and had a resistance of ∼1M Ω.
The holding potential was -60 mV. To determine EC50
values, concentration-response data were ﬁtted to the four-
parameter logistic equation I ) Imin + (Imax - Imin)/[1 +
10log(EC50-[A])nH], where Imax is the maximal response plateau,
Imin is the minimum response plateau, [A] is the concentration
of agonist, and nH is the Hill coefﬁcient, using PRISM
version 4.03 (GraphPad, San Diego, CA). Relative efﬁcacies
of the partial agonists mCPBG, 5-FT, and tryptamine are
reported as Rmax ) Imax(drug)/Imax(5-HT). One-way ANOVAs
were performed with a Dunnett’s post test to determine
statistical signiﬁcance. Data are quoted as means ( the
standard error of the mean (n) unless otherwise stated.
[3H]Granisetron Binding to Oocytes. For single-point
radioligand binding assays, 20-40 oocytes were homog-
enized in 200 µL of 10 mM HEPES (pH 7.4) containing
protease inhibitors (1 mM EDTA, 50 µg/mL soybean trypsin
inhibitor, 50 µg/mL bacitracin, and 0.1 mM PMSF) and 1%
Triton X-100. Following a 10 min incubation at room
temperature, oocyte yolk proteins were pelleted by centrifu-
gation at 13000g for 10 min. The supernatant was retained,
avoiding the uppermost lipid layer. Single-point assays were
performed in 500 µL of 10 mM HEPES (pH 7.4) containing
25 µL of oocyte preparation and 0.5 nM [3H]granisetron
(63.5 Ci/mmol; Perkin-Elmer, Inc.). Nonspeciﬁc binding was
determined using 10 µM quipazine (Tocris). Tubes were
incubated at 4 °C for 1 h before bound radioligand was
harvested by rapid ﬁltration onto GF/B ﬁlters presoaked in
0.3% polyethylenemine. Filters were then washed with two
3 mL washes of ice-cold HEPES buffer and left in 3 mL of
scintillation ﬂuid (Ecoscint A; National Diagnostics) for at
least 4 h before scintillation counting was conducted to
determine amounts of membrane-bound radioligand.
Modeling. The modeling was performed as described
previously (13). Brieﬂy, an alignment of the mouse 5-HT3A
receptor extracellular domain (GenBank accession number
Q6J1J7) with the Lymnaea stagnalis AChBP (GenBank
accession number P58154) was performed using ClustalX
and then modiﬁed by the insertion of a single-amino acid
gap into the AChBP sequence following D85 (WVPD-
LAAYNAISKP) and a single-amino acid gap into the 5-HT3
receptor subunit sequence following V131 (WVPDILINEFV-
DVG). The new model of the 5-HT3 receptor extracellular
domain based on the AChBP structure (Protein Data Bank
entry 1I9B) was then built using MODELER 6v2 (17)a s
described previously (5).
RESULTS
Wild-type (WT) receptors displayed large, rapidly activat-
ing and desensitizing currents (Figure 3) with an EC50 of
1.2 µM for 5-HT (pEC50 ) 5.93 ( 0.01; n ) 10). The partial
agonists mCPBG, 5-FT, and tryptamine had EC50 values of
0.47, 18, and 120 µM, respectively (Tables 1 and 2 and
Figure 4). mCPBG was almost as efﬁcacious as 5-HT at these
receptors, with an Rmax of 0.81 ( 0.02 (n ) 14). The Rmax
for 5-FT was 0.44 ( 0.02 (n ) 19). However, for tryptamine,
the Rmax was only 0.09 ( 0.01 (n ) 8); these small currents
precluded systematic data recording in a number of
experiments.
Asn128 Mutants. Replacement of Asn128 with Asp, Glu,
Ala, and the unnatural amino acid Akp resulted in no or small
changes in 5-HT, mCPBG, and 5-FT EC50 values, although
Hill coefﬁcients for 5-HT were reduced (Tables 1 and 2 and
Figure 4) . In contrast, replacement with Gln or Lys resulted
in signiﬁcant increases in EC50 values for 5-HT, mCPBG,
and 5-FT, while replacement with Val signiﬁcantly decreased
the EC50. There were no changes in Hill coefﬁcients for these
three mutants (Tables 1 and 2). For the N128R mutant, the
efﬁcacy of 5-HT appeared to be signiﬁcantly reduced (Figure
5A), but responses to 5-HT were too small to allow a
determination of EC50. Most of the mutations (all except Ala
and Val) also resulted in changes to mCPBG Rmax values;
these were increased 2-19-fold compared to that of WT
(Figure 5B). There were also changes in the current proﬁle
for some mutants. N128V and N128Q substitution resulted
in an apparent slower activation rate and no obvious
desensitization in the continued presence of 5-HT (Figure
3B). A detailed kinetic analysis of these changes would
require single-channel analyses, which are not possible with
these receptors (<1 pS conductance), but the clear changes
in the macroscopic data between WT and mutant receptors
are consistent with changes to receptor activation and
desensitization.
6372 Biochemistry, Vol. 47, No. 24, 2008 Price et al.Glu129 Mutants. E129D, E129N, and E129Q exhibited
robust responses to 5-HT (Figure 3C). E129H responses were
small and only measurable if recorded >72 h postinjection.
E129G and E129K mutants failed to respond to high
concentrations (100 µM) of either 5-HT or mCPBG. The
unnatural amino acid Nha, which is isoelectronic and isosteric
to Glu but which lacks charge, had an EC50 for 5-HT similar
to that of WT, as did E129D. Overall EC50 values for 5-HT
were in the following rank order: WT < E129D < E129Nha
< E129H < E129N < E129Q (Figure 4). Hill coefﬁcients
of all the functional mutants were reduced compared to that
of WT (Tables 1 and 2). Interestingly, E129Q mutant
receptors failed to be activated by mCPBG; instead, mCPBG
acted as an antagonist and was able to block 5-HT-induced
currents, as previously reported (9). In our study, mCPBG
blocked 100 µM 5-HT-induced currents with an IC50 of 0.63
µM [pIC50 ) 6.20 ( 0.04 M; n ) 5 (Figure 6)]. Furthermore,
5-FT, another partial agonist of 5-HT3 receptors (18), also
became an antagonist, blocking 100 µM 5-HT-induced
currents with an IC50 of 13 µM [pIC50 ) 5.26 ( 0.06; n )
3 (Figure 6)]. Like mCPBG, this compound failed to activate
E129Q mutant receptors on its own.
We also tested whether granisetron could inhibit 5-HT-
induced responses from these mutant receptors. At E129D
receptors, 10 nM granisetron was able to block 80 ( 5% (n
) 3) of the response to an EC50 concentration of 5-HT and
96 ( 3% at 100 nM, and recovery from granisetron block
was complete in <3 min, compared with >15 min at WT
receptors. Granisetron was less potent at E129N receptors,
where 100 nM granisetron did not block the response to an
EC50 concentration of 5-HT.
FIGURE 3: Examples of current traces. (A) Typical responses to maximal concentrations of 5-HT, mCPBG, 5-FT, and tryptamine from the
same oocyte expressing WT 5-HT3 receptors. (B) Typical 5-HT responses of oocytes expressing Asn128 mutant receptors; [5-HT] ) 22
µM, except for N128Q (200 µM) and N128-Nha (48 µM). (C) Typical 5-HT and mCPBG responses from oocytes expressing Glu129
mutant receptors.
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and Glu129 mutant receptors expressed in HEK cells (13).
For Asn128 mutant receptors, there were no signiﬁcant
differences in [3H]granisetron binding afﬁnity for any
substitution studied, while no speciﬁc binding was observed
for any Glu129 mutant receptor, at concentrations up to 20
nM. In the study presented here, we examined single-point
[3H]granisetron binding to solubilized oocyte preparations
(it requires very large numbers of oocytes to create [3H]g-
ranisetron saturation binding curves and therefore is not
practical). No speciﬁc radioligand binding was observed at
0.5 nM [3H]granisetron for E129A, E129G, and E129K
mutant receptors, while levels of binding in Asn128 receptors
were similar to those in WT receptors (Figure 7). These data
suggest that Glu129 substitutions ablate high-afﬁnity an-
tagonist binding, but at least some substitutions permit
agonist binding, as large (>5 µA) responses to 5-HT and
mCPBG were observed for E129D and E129N receptors.
DISCUSSION
The data described here support a modiﬁed 5-HT3 receptor
homology model (13), in which Glu129, rather than Asn128,
faces into the binding pocket. The data indicate a critical
hydrogen bond between Glu129 and the hydroxyl of 5-HT,
which places this residue ﬁrmly in the binding pocket.
Asn128 may play a role in receptor gating, but the data show
that it is not directly involved in binding ligands, as
previously proposed (5).
Loop A was identiﬁed many years ago as a region that
contributes to ligand binding in nACh receptors; afﬁnity
labeling with [3H]ACh mustard indicated the positive charge
of ACh was positioned near the loop A residue Tyr93 (19).
There was also evidence for a contribution from neighboring
Asn94 (20), and a detailed functional analysis of Asp97 has
led to the proposal that loop A could be compared to a latch,
which holds the channel closed in the absence of agonists,
and reduces the probability of channel opening (11). More
recent studies, in particular the high-resolution structure
determination of AChBP, conﬁrm the importance of the loop
A Tyr at position 89 (equivalent to Tyr93 in nAChR) which
is in close contact with bound ligands (21). The aligned Tyr
is also important in GABAA receptors; Tyr97 in the  2
subunit has recently been shown to make a cation-π
interaction with GABA (22). It was therefore not surprising
that the aligning residue in the 5-HT3 receptor, Asn128, was
considered to be important. Homology modeling identiﬁed
it as the only loop A residue in the binding pocket and
predicted a hydrogen bond between Asn128 and 5-HT (5).
However, experimental studies have cast some doubt on this
conclusion, as changing Asn128 did not affect [3H]granis-
etron binding afﬁnity (13).
Our new data, incorporating both natural and unnatural
amino acids at this position, provide a detailed analysis of
the role of Asn128 and strongly suggest that Asn128 has its
most signiﬁcant role in the conformational change that results
in receptor gating. All Asn128 mutant receptors exhibited
changes in their functional characteristics (Figure 2), but
these were particularly evident in N128Q receptors. Gln has
chemical properties similar to those of Asn, yet this mutation
markedly slows apparent current activation, increases the
Table 1: 5-HT and mCPBG EC50 Values and Hill Coefﬁcients for N128 and E129 Mutant Receptors
a
receptor 5-HT pEC50 5-HT EC50 (µM) nH mCPBG pEC50 mCPBG EC50 (µM) nH
WT 5.93 ( 0.01 1.2 2.54 ( 0.15 6.33 ( 0.02 0.47 2.03 ( 0.23
N128A 5.44 ( 0.03 3.6 1.34 ( 0.13
b 5.95 ( 0.02 1.1 1.33 ( 0.08
N128D 5.51 ( 0.01 3.1 1.63 ( 0.08
b 6.56 ( 0.03 0.27 1.54 ( 0.15
N128E 5.68 ( 0.04 2.1 1.48 ( 0.18
b 6.56 ( 0.03 0.28 1.81 ( 0.019
N128Q 4.64 ( 0.03
b 23 2.11 ( 0.29 5.52 ( 0.18
b 3.0 2.41 ( 0.16
N128R SR SR SR 5.14 ( 0.02
b 7.3 1.93 ( 0.16
N128K 4.47 ( 0.03
b 34 2.13 ( 0.38 5.41 ( 0.03
b 3.9 1.43 ( 0.16
N128V 7.04 ( 0.02
b 0.091 3.18 ( 0.60 7.13 ( 0.02
b 0.074 5.07 ( 0.85
b
N128-Akp 5.33 ( 0.01
b 4.6 1.49 ( 0.06
b ND ND ND
N128-Nha SR SR SR 5.55 ( 0.02
b 2.8 2.18 ( 0.23
E129A NR NR NR NR NR NR
E129D 5.73 ( 0.03 1.9 1.81 ( 0.16
b 6.60 ( 0.10 0.25 1.19 ( 0.31
E129G NR NR NR NR NR NR
E129H 4.85 ( 0.09
b 14 1.07 ( 0.24
b 6.43 ( 0.04 0.37 1.63 ( 0.20
E129K NR NR NR NR NR NR
E129N 4.25 ( 0.02
b 56 1.17 ( 0.07
b 6.21 ( 0.05 0.62 1.25 ( 0.19
E129Q 3.93 ( 0.01
b 120 1.55 ( 0.07
b NR NR NR
E129-Nha 5.45 ( 0.04 3.5 1.18 ( 0.12
b 6.25 ( 0.07 0.56 1.91 ( 0.60
a Data are means ( the standard error of the mean (n ) 3-16). NR indicates no response. SR indicates small (<100 nA) responses. ND indicates
not determined.
b Signiﬁcant difference p < 0.05 and for pEC50 values >3-fold different from that of WT.
Table 2: 5-FT and Tryptamine EC50 Values and Hill Coefﬁcients for N128 and E129 Mutant Receptors
a
receptor 5-FT pEC50 EC50 (µM) nH tryptamine pEC50 EC50 (µM) nH
WT 4.75 ( 0.02 18 2.71 ( 0.24 3.93 ( 0.01 120 2.86 ( 0.14
N128A 5.00 ( 0.06 10 2.34 ( 0.75 4.04 ( 0.03 91 2.90 ( 0.68
N128D 4.75 ( 0.02 18 2.61 ( 0.28 SR --
N128E 4.86 ( 0.02 14 1.97 ( 0.18 4.23 ( 0.03 59 2.90 ( 0.53
N128Q 4.03 ( 0.05
b 94 2.38 ( 0.58 3.62 ( 0.02 240 3.10 ( 0.39
E129D 5.08 ( 0.04 8.3 1.95 ( 0.30 SR --
E129N 4.93 ( 0.04 12 1.25 ( 0.13
b SR --
a Data are means ( the standard error of the mean (n ) 3-13). SR indicates small (<100 nA) responses.
b Signiﬁcant difference p < 0.05 and for
EC50 values >3-fold different from that of WT.
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eliminates receptor desensitization (Figures 3 and 4). Changes
in current activation and Rmax strongly suggest effects on
receptor opening, and while desensitization is not well
understood, it is known to be inﬂuenced by channel opening
and closing rates and the rates of conformational changes to
and from the desensitized state. These observations therefore
all suggest that Asn128 has a role in facilitating transitions
between conformational states rather than direct effects upon
ligand binding. In the new model, this residue is close to
loop B, especially Thr179, and both these residues contribute
to a complex network of hydrogen bonds that could
potentially be involved in the conformational change that
results in receptor gating.
Receptors with substitutions at Glu129 have, in the past,
been insufﬁciently characterized due to problems with low
levels of expression (9, 13). In this study, these problems
have been largely overcome by the use of Xenopus oocytes
as expression hosts. Large responses to 5-HT and the partial
agonists mCPBG and 5-FT were measured with mutants of
Glu129 that did not previously display measurable currents
when expressed in HEK293 cells. Interestingly, only the
Glu129 mutant receptors in which Glu was replaced with
residues that have the ability to accept a hydrogen bond
responded robustly to 5-HT application, suggesting that this
property is critical for 5-HT binding. Previously published
ligand docking data have indicated that the hydroxyl of 5-HT
is located in this region of the binding pocket, and in the
new model, this hydroxyl would donate a hydrogen bond to
Glu129; more speciﬁcally, one of the side chain O atoms of
Glu129 would interact with the hydrogen of the 5-HT
5-hydroxyl (Figure 8). Note that an ionic interaction involv-
ing Glu129 is not supported by our data with the unnatural
amino acid Nha. This amino acid is structurally similar to
Glu: The nitro group is planar, like the carboxylate, and the
two N-O bonds are of equal length, as are the C-O bonds
in the carboxylate. Two resonance structures are possible
(as with carboxylate), but in a nitro group, the N atom carries
a positive charge and the O atoms share a negative charge;
thus, overall the group is neutral, in contrast to the negative
charge on a carboxylate. A nitro group could therefore not
contribute to an ionic bond. As there was no signiﬁcant
increase in EC50 when Nha was substituted for Glu, it shows
that an ionic bond is not formed here. Nha could, however,
still form a hydrogen bond as each O in the nitro group has
two lone pairs of electrons (as does the carboxylate), which
can serve as hydrogen bond acceptors.
Interestingly, mutations at Glu129 have no effect on the
EC50 values of the partial agonists mCPBG and 5-FT. This
might be expected with mCBPG, which has a structure
distinct from that of 5-HT and is unlikely to interact with
identical binding site residues, but the only difference
between 5-HT and 5-FT is the group at the 5 position. The
OH group of 5-HT is a good hydrogen bond donor and a
moderately good hydrogen bond acceptor; however, the F
of 5-FT cannot donate a hydrogen bond and is a very poor
hydrogen bond acceptor. Thus, if 5-FT binds in the same
orientation as 5-HT, which seems likely, it is probable that
there is no hydrogen bond here with Glu129, a hypothesis
that is supported by the data. The lack of this bond may be
the reason why 5-FT acts as only a partial agonist.
If Glu129 interacts directly with 5-HT, then it must face
into the binding site and could interact with antagonists. Our,
and previously published, data support this proposal: there
is no speciﬁc [3H]granisetron binding to Glu129 mutant
receptors in either HEK cells or oocyte membranes in the
usual subnanomolar range (13). Interestingly, though, gra-
nisetron does appear to be able to bind to E129D mutant
receptors at higher concentrations, as 10 nM granisetron
inhibited ∼80% of 5-HT-induced currents [WT IC50 ) 0.2
nM (23)]. Combined with the fact that E129D mutant
receptors recover more quickly than WT receptors from
granisetron inhibition, these data suggest that E129D mutant
FIGURE 4: Concentration-response data for wild-type (WT) and
mutant 5-HT3 receptors. Data are means ( the standard error of
the mean. Parameters of the ﬁtted curves are listed in Tables 1
and 2.
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isetron. Such an explanation is consistent with previous
equilibrium radioligand binding studies, where an ∼100-fold
increase in the granisetron Kd was reported (9).
Our data also reveal small but signiﬁcant changes in
relative efﬁcacies for mCPBG at functional Glu129 mutant
receptors, indicating there also may be a role for this residue
in the conformational changes leading to receptor gating.
These changes are opposite to those we observed with
Asn128. We do not yet understand what this implies,
although it may be related to the different roles of the two
residues and/or distinct mechanisms of action or critical
binding residues used by different agonists. In support of
FIGURE 5: Relative efﬁcacy (Rmax)o fmCBPG at WT and (A) N128 and (B) E129 mutant receptors. Data are means ( the standard error
of the mean (n > 3). Note the substantial change in the range of efﬁcacies in panel B vs panel A. The asterisk indicates a value signiﬁcantly
different from that of WT (p < 0.05).
FIGURE 6: mCPBG and 5-FT are antagonists at E129Q receptors.
Concentration-response data showing inhibition of the 100 µM
5-HT-induced response. Each agonist was co-applied with 5-HT.
Responses are normalized to the response to 5-HT alone. Data are
means ( the standard error of the mean (n ) 3-6).
FIGURE 7: Antagonist binding to 5-HT3 receptors expressed in
oocytes. Speciﬁc binding of 0.5 nM [3H]granisetron to oocyte
membrane samples. Data are means ( the standard error of the
mean (n ) 4).
FIGURE 8: New model of 5-HT3 receptor binding site, showing 5-HT
hydrogen bonded to Glu129. This model is that described by
Sullivan et al. (13) in which a single-amino acid gap was inserted
into the 5-HT3A receptor subunit sequence (GenBank accession
number Q6J1J7) following V131 (WVPDILINEFV-DVG). The new
model of the complete mouse 5-HT3A receptor extracellular domain
was then built using L. stagnalis AChBP (GenBank accession
number P58154, PDB entry 1I9B) as a template. The locations of
Asn128, Glu129, and Trp183 relative to 5-HT are shown. The
proposed H-bond between Glu129 and the hydroxyl group of 5-HT
is colored green.
6376 Biochemistry, Vol. 47, No. 24, 2008 Price et al.this latter hypothesis, a similar study on a series of loop C
residues, which are also proposed to play roles in binding
and/or gating, revealed increases in mCPBG efﬁcacy but
decreases in the efﬁcacy of another partial agonist, 2-methyl-
5-HT, in the same mutant receptors (24). In our study, the
conversion of mCPBG from a partial agonist to an antagonist
at E129Q mutant receptors could reﬂect a change in the
afﬁnity of mCPBG for certain conformational states of the
receptor only (e.g., a reduction in afﬁnity of the open state
but not the closed state). This would correspond to the “K”
phenotype of allosteric receptor mutants described by Galzi
et al. (25).
The importance of Glu129 suggests it may be equivalent
to Tyr93 in the nACh receptor, which has also been proposed
to play a role in both binding and function. Mutating Tyr93
results in a rightward shift of the dose-response curve (26),
mainly because of slower ligand association and channel
opening rate constants (27). Similarly, the equivalent residue
in the GABAA receptor,  2Tyr97, which directly contacts
GABA through a cation-π interaction (22), may also be
involved in gating; mutation to Cys causes spontaneous
activation (10). Aligning Glu129 and Tyr93 requires that a
space be inserted in the conserved WxPDxxxN domain in
loop A of the nACh receptor. This sequence is critical for
locating the B loop in the nACh receptor through interactions
involving Asp89 (28). More recent data, however, show that
in non-ACh receptors the xxxN portion of this region may
not be critical; in the GABAA receptor, for example, two
amino acid “spaces” must be inserted in the ‘xxx’ tract to
allow  2Tyr97 to contribute to the binding pocket. We
therefore propose that Glu129 is equivalent to Tyr93 and
faces into the binding pocket, where it forms a hydrogen
bond with the 5-OH group of 5-HT.
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